

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/560,069
(Use as many sheets as necessary) (Use as many sheets as necessary)				Filing Date	March 14, 2007
Sheet	1	1		First Named Inventor	Stephen John KENT
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	23558-007US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	GJERTSEN M K ET AL., " Vaccination with Mutant RAS Peptides and Induction of T-Cell Responsiveness in Pancreatic Carcinoma Patients Carrying the Corresponding RAS Mutation", Lancet Limited. London, GB, vol. 346, No. 8987, pp. 1339-1400	
	B2	ROEDERER M. ET AL., "Optimized Determination of T Cell Epitope Responses" Journal of Immunological Methods, vol. 274, No. 1-2, March 2003, pp. 221-228	
	B3	KENT STEPHEN J ET AL., "Enhanced Cellular Immunity in Macaques Following a Novel Peptide Immunotherapy (OPAL)", Journal of Medical Primatology, vol. 35, No. 4-5, August 2006, pp. 315-316, XP002409423	
	B4	NICHOLAS S. WILSON, et al., "Dendritic Cells Constitutively Present Self Antigens in Their Immature State in Vivo and Regulate Antigen Presentation by Controlling the Rates of MHC Class II Synthesis and Endocytosis," BLOOD, March 2004, vol. 103, No. 6, pp. 2187-2195	
	B5		
	B6		
	B7		
	B8		
	B9		
	B10		
	B11		
	B12		
	B13		
	B14		
	B15		
	B16		
	B17		
	B18		
	B19		
	B20		
	B21		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

